Website intended for a NZ health professional readership
We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 28 February.
Sports physician Steve Targett discusses the importance of regular screening for pelvic floor disorders in exercising women and introduces a new screening tool
1. Dakic JG, Cook J, Hay-Smith J, et al. Pelvic floor disorders stop women exercising: A survey of 4556 symptomatic women. J Sci Med Sport 2021;24(12):1211–17.
2. Dakic JG, Hay-Smith EJC, Lin KY, et al. Women’s preferences for pelvic floor screening in sport and exercise: a mixed-methods study integrating survey and interview data in Australian women. Br J Sports Med 2023;57(24):1539–49.
3. Giagio S, Salvioli S, Innocenti T, et al. PFD-SENTINEL: Development of a screening tool for pelvic floor dysfunction in female athletes through an international Delphi consensus. Br J Sports Med 2023;57(14):899–905.
4. Forner LB, Beckman EM, Smith MD. Do women runners report more pelvic floor symptoms than women in CrossFit®? A cross-sectional survey. Int Urogynecol J 2021;32(2):295–302.
5. Woodley SJ, Lawrenson P, Boyle R, et al. Pelvic floor muscle training for preventing and treating urinary and faecal incontinence in antenatal and postnatal women. Cochrane Database Syst Rev 2020;5(5):CD007471.
6. Christopher SM, Donnelly G, Brockwell E, et al. Clinical and exercise professional opinion of return-to-running readiness after childbirth: an international Delphi study and consensus statement. Br J Sports Med 2023; 26 December online.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
